Introduction to C1QBP, A Potential Drug Target (G708)

Target Name: C1QBP

NCBI ID: G708

C1QBP

Introduction to C1QBP, A Potential Drug Target

C1QBP, also known as Complement Component 1 Q Subcomponent Binding Protein, is a versatile protein that has garnered significant attention in the field of drug discovery. It serves both as a potential drug target and a biomarker for various diseases. In this article, we will explore the multifaceted roles of C1QBP and delve into its potential application in medical research and therapeutics.

The Versatility of C1QBP

C1QBP is a highly conserved protein found in diverse organisms ranging from bacteria to humans. It is primarily localized in the mitochondria, endoplasmic reticulum, cytoplasm, and plasma membrane. This wide distribution indicates its involvement in vital cellular processes.

C1QBP as a Drug Target

One of the significant aspects of C1QBP is its role as a potential drug target. Several studies have revealed its association with various diseases, making it an attractive candidate for therapeutic intervention. Its involvement in cancer progression, viral infections, and neurodegenerative disorders has positioned C1QBP as an important target for drug development.

In cancer research, C1QBP has shown promise as a target due to its ability to regulate cell proliferation, migration, and invasion. It is overexpressed in numerous cancer types, including breast, lung, prostate, and ovarian cancers. Inhibition of C1QBP has been observed to suppress tumor growth and metastasis, demonstrating its therapeutic potential.

Additionally, C1QBP has been implicated in viral infections, such as hepatitis C and influenza. These viruses exploit C1QBP to enhance their entry into host cells, making it an attractive target for antiviral therapy. Blocking C1QBP's interaction with viral proteins could potentially inhibit viral replication and spread, leading to improved treatment strategies against these infections.

Furthermore, neurodegenerative disorders, including Alzheimer's and Parkinson's disease, have been associated with C1QBP dysregulation. It has been found to accumulate in brain tissues of patients affected by these conditions. Targeting C1QBP may thus provide a novel approach for developing therapies to combat these devastating diseases.

C1QBP as a Biomarker

Apart from its potential as a drug target, C1QBP also holds promise as a biomarker for multiple diseases. Biomarkers are measurable indicators that can aid in diagnosis, prognosis, and monitoring of diseases. C1QBP has shown potential in this aspect due to its differential expression levels in various pathologies.

In cancer, C1QBP levels have been found to be significantly elevated in patient samples compared to healthy individuals. Consequently, it can serve as a diagnostic biomarker for early cancer detection. Moreover, monitoring C1QBP levels during treatment can help assess therapy efficacy and patient response.

C1QBP has also demonstrated its significance in cardiovascular diseases. It is associated with atherosclerosis, a condition characterized by the deposition of fatty plaques in arterial walls. Elevated C1QBP levels have been observed in atherosclerotic patients, making it a potential biomarker for disease detection and risk assessment.

Additionally, C1QBP has been implicated in autoimmune diseases, such as systemic lupus erythematosus (SLE) and rheumatoid arthritis (RA). Altered expression of C1QBP has been observed in patients with these conditions, indicating its potential as a diagnostic and prognostic biomarker.

Conclusion

In conclusion, C1QBP plays a crucial role as both a drug target and a biomarker in various diseases. Its involvement in cancer, viral infections, neurodegenerative disorders, cardiovascular diseases, and autoimmune conditions highlights its versatility and therapeutic potential. Further research and development in understanding C1QBP's mechanisms and its modulation through targeted therapies may pave the way for innovative and effective treatments in the future.

Protein Name: Complement C1q Binding Protein

Functions: Is believed to be a multifunctional and multicompartmental protein involved in inflammation and infection processes, ribosome biogenesis, protein synthesis in mitochondria, regulation of apoptosis, transcriptional regulation and pre-mRNA splicing. At the cell surface is thought to act as an endothelial receptor for plasma proteins of the complement and kallikrein-kinin cascades. Putative receptor for C1q; specifically binds to the globular 'heads' of C1q thus inhibiting C1; may perform the receptor function through a complex with C1qR/CD93. In complex with cytokeratin-1/KRT1 is a high affinity receptor for kininogen-1/HMWK. Can also bind other plasma proteins, such as coagulation factor XII leading to its autoactivation. May function to bind initially fluid kininogen-1 to the cell membrane. The secreted form may enhance both extrinsic and intrinsic coagulation pathways. It is postulated that the cell surface form requires docking with transmembrane proteins for downstream signaling which might be specific for a cell-type or response. By acting as C1q receptor is involved in chemotaxis of immature dendritic cells and neutrophils and is proposed to signal through CD209/DC-SIGN on immature dendritic cells, through integrin alpha-4/beta-1 during trophoblast invasion of the decidua, and through integrin beta-1 during endothelial cell adhesion and spreading. Signaling involved in inhibition of innate immune response is implicating the PI3K-AKT/PKB pathway. Required for protein synthesis in mitochondria (PubMed:28942965). In mitochondrial translation may be involved in formation of functional 55S mitoribosomes; the function seems to involve its RNA-binding activity. May be involved in the nucleolar ribosome maturation process; the function may involve the exchange of FBL for RRP1 in the association with pre-ribosome particles. Involved in regulation of RNA splicing by inhibiting the RNA-binding capacity of SRSF1 and its phosphorylation. Is required for the nuclear translocation of splicing factor U2AF1L4. Involved in regulation of CDKN2A- and HRK-mediated apoptosis. Stabilizes mitochondrial CDKN2A isoform smARF. May be involved in regulation of FOXC1 transcriptional activity and NFY/CCAAT-binding factor complex-mediated transcription. May play a role in antibacterial defense as it can bind to cell surface hyaluronan and inhibit Streptococcus pneumoniae hyaluronate lyase. May be involved in modulation of the immune response; ligation by HCV core protein is resulting in suppression of interleukin-12 production in monocyte-derived dendritic cells. Involved in regulation of antiviral response by inhibiting RIGI- and IFIH1-mediated signaling pathways probably involving its association with MAVS after viral infection

The "C1QBP Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about C1QBP comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets